Objective: We compared bone mineral density (BMD) changes and their correlates, between men and women participating in two randomized trials of initial [antiretroviral therapy (ART)] regimens, with or without tenofovir disoproxil fumarate (TDF).
Introduction
Persons living with HIV (PLWH) on antiretroviral therapy (ART) have a higher prevalence of osteoporosis and an increased fracture risk compared with the general population [1] [2] [3] [4] [5] . Average bone mineral density (BMD) declines of 2-6% develop predominately during the first year of ART. The largest of these declines are associated with regimens that include tenofovir disoproxil fumarate (TDF) or protease inhibitors [6] [7] [8] [9] where, increasing cumulative exposure to these agents also are associated with higher incidence of fracture [10] . PLWH also have an overrepresentation of traditional risk factors for bone loss, which combined with the detrimental effects on bone by ART and other HIV-specific factors, also contribute to lower BMD and increased fracture risk [10] [11] [12] [13] .
Among PLWH, women have faster rates of bone loss, maintain lower BMD and have higher rates of fracture than men [3, 14, 15] . It is not known whether, or to what extent the detrimental effects of ART on bone, or other HIV-specific correlates of bone loss, differ between men and women. To examine this question, we compared hip and spine BMD changes, and their correlates, between men and women during the first 48 weeks of initial ART in participants of two multicenter AIDS Clinical Trials Group randomized trials (ACTG studies A5224s and A5303).
Methods

Study design and treatment regimen
A5224s is a metabolic substudy of a larger trial that compared TDF-emtricitabine vs. abacavir-lamivudine, combined with either efavirenz or atazanavir and ritonavir as initial ART [5, 16] . A5303 compared initial ART with TDF vs. maraviroc, each combined with emtricitabine and darunavir and ritonavir [17] . ARTnaive participants with plasma viral load (pVL) more than 1000 copies/ml, who were at least 16 years for A5224s, or at least 18 years for A5303, were eligible to participate. Eligibility for A5224s was additionally restricted to participants who did not use medications for osteoporosis, and eligibility for A5303 was restricted to participants with R5 tropism. Additional information can be found about these studies at ClinicalTrials.gov: NCT 00118898 and 01400412.
The Institutional Review Board of each study site approved the protocol. All participants provided written informed consent.
Measurements of bone mineral density, phosphaturia and bone turnover Dual energy X-ray absorptiometry (DXA) scans of the left hip and lumbar spine (L1-L4) were performed within 4 weeks prior to randomization, using either a Lunar (GE Healthcare, Fairfield, Connecticut, USA) or Hologic (Hologic Incorporated, New Bedford, Massachusetts, USA) DXA scanner. A second scan was performed at week 48 (AE4 weeks) using the same scanning system. All DXA scans were read centrally at the Body Composition Analysis Center at Tufts University. The European Spine Phantom was used for cross-calibration of DXA machines and quality assurance at each study site.
Phosphaturia was measured as the weeks 0-48 area under the curve of the fractional excretion of phosphate (FEP-AUC) from urine and serum specimens collected at weeks 0 and 48, calculated using the trapezoidal rule [18, 19] .
Bone turnover was measured in A5303 participants only, at weeks 0, 24 and 48 in plasma as C-terminal telopeptides of type I collagen (CTx) and procollagen 1 intact Nterminal propeptide (P1NP). CTx was measured by ELISA (Immunodiagnostic Systems, Scottsdale, Arizona, USA) with interassay and intra-assay variabilities of 9.7 and 1.7%, respectively (normal range: 0.142-1.351 pg/ ml for postmenopausal women). P1NP was measured by radioimmunoassay (Immunodiagnostic Systems) with interassay and intra-assay variabilities of 8.3 and 6.5%, respectively (normal range 16-96 pg/ml for postmenopausal women).
Statistical analysis
Baseline and 48-week changes from baseline in timevarying covariates were compared by sex, and by randomization to TDF vs. non-TDF-containing regimens, using the Wilcoxon rank-sum test for continuous, and the Pearson chi-square test for categorical variables. Baseline for all covariates except BMD was defined as the randomization date (designated as week 0); baseline for BMD measurements was defined as up to 4 weeks before randomization. The exploratory covariates included baseline serum phosphate and 48-week FEP-AUC, as well as baseline and 48-week changes from baseline in CD4 þ cell counts, glomerular filtration rate (GFR) [using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation], CTx and P1NP.
Separate multivariable linear regression models tested the independent contributions to baseline hip and spine BMD and to the 48-week changes from baseline of BMD by each exploratory variable. Adjusting variables that were retained in the models regardless of significance included age, sex, race (as black, not Hispanic vs. white, Hispanic regardless of race or other races/ethnicities), baseline hip or spine BMD, randomization status to TDF vs. non-TDF-containing regimens, baseline pVL and pVL at week 48 (as <50 vs. !50 HIV RNA copies/ml). Models of hip BMD were additionally adjusted for baseline BMI.
These models were extended to test interactions by sex and randomization status, in which significance was defined by P less than 0.10. Stratified, unadjusted models by sex and randomization status explored any significant interactions that were detected. All analyses used SAS version 9.4 (SAS Institute, Cary, North Carolina, USA).
Results
Included in this analysis were 499 participants, 433 of whom had baseline and week-48 hip or spine BMD measurements (Table 1) . Complete CD4 þ cell and phosphaturia data were available in 429 and 374 of these 433 participants, respectively. Turnover markers were measured only in A5303 participants (n ¼ 220). Data from participants who represented extreme outliers in the distributions of hip BMD changes (n ¼ 3), or of the 48-week FEP-AUC (n ¼ 4) were excluded for the linear regression models.
Participants randomized to TDF vs. non-TDF-containing regimens had significantly more hip (3.6 vs. 2.4%, P < 0.0001; Table 2 ) and spine BMD decline (3.6 vs. 1.9%, P < 0.0001). They also had significantly larger increases in bone turnover markers (P < 0.0001, for CTx Antiretroviral-therapy-associated bone decline Kalayjian et al. 2519 Table 1 . Baseline characteristics by randomization to tenofovir disoproxil fumarate vs. nontenofovir disoproxil fumarate-containing regimens and by sex. Sixty-one (12%) participants were women, who were significantly older (40 vs. 37 years, P ¼ 0.02) and more likely to be black than the men (28 vs. 48%, P < 0.0001). They also had significantly higher baseline BMI (P ¼ 0.03) and serum phosphate concentrations (P ¼ 0.001), significantly lower FEP-AUC (P ¼ 0.03), and a trend toward larger increases in the bone formation marker P1NP (P ¼ 0.07).
Randomization status Sex
Correlates of baseline spine bone mineral density Women had a 0.39 g/cm 2 (P ¼ 0.04) lower average baseline spine BMD than men in adjusted models. Baseline BMI (P < 0.0001) and serum phosphate concentrations were positively associated with baseline spine BMD, but the latter association depended on sex (P ¼ 0.04 for the interaction by sex; n ¼ 59 women, 415 men; Fig. 1a and Supplementary Table, http:// links.lww.com/QAD/B354). In stratified analyses, serum phosphate was positively associated with BMD in women (P ¼ 0.03) but not men (P ¼ 0.97).
Baseline and time-varying correlates of 48-week spine bone mineral density changes Participants randomized to TDF vs. non-TDF-containing regimens had a 1.8% larger average spine BMD decline (P < 0.0001) in adjusted models (Supplementary  Table, http://links.lww.com/QAD/B354). BMD change was positively associated with baseline spine BMD (P ¼ 0.0002), negatively associated with baseline pVL (1.3% greater decline per every 1 log 10 greater HIV-RNA copies/ml; P < 0.0001) and positively associated with viral suppression at week 48 (1.0% less BMD decline with suppression to <50 vs. !50 copies/ml; P ¼ 0.02). Women had a 0.6% larger average BMD decline than men, but this difference was NS (P ¼ 0.35).
Phosphaturia, DCD4
þ cells, DGFR and bone turnover markers were significantly associated with 48-week spine BMD changes in separate, adjusted models (Supplementary Table, http://links.lww.com/QAD/B354). Sexmodified associations with phosphaturia, and randomization status modified associations with phosphaturia and DGFR.
Each 2% increased FEP-AUC was associated with a 0.8% (P ¼ 0.03) larger average spine BMD decline in women vs. men, and with a 0.4% (P ¼ 0.054) larger average decline in participants randomized to TDF vs. non-TDFcontaining regimens (Supplementary Table, http:// links.lww.com/QAD/B354). In analyses stratified by sex among participants randomized to TDF regimens, this magnitude of phosphaturia was associated with a 1.4% average decline in women (P ¼ 0.03, Fig. 1b ) but was not significantly associated with BMD changes in men (P ¼ 0.17). Phosphaturia was not associated with BMD spine changes in participants randomized to non-TDF-containing regimens, regardless of sex.
Associations between DGFR and spine BMD decline also depended on randomization status. A 5 ml/min per 1.73 m 2 GFR decline over 48 weeks was associated with a 0.4% larger average BMD decline in participants randomized to TDF vs. non-TDF regimens (P ¼ 0.01 for the interaction by randomization status; Fig. 1c and Supplementary Table, http://links.lww.com/QAD/B354). In stratified analyses, this association was also only significant among participants randomized to TDF regimens (P ¼ 0.01).
Changes in spine BMD on ARTwas negatively associated with DCD4 þ , with an average BMD decline of 0.3% for every 100 CD4 þ cells/ml increase (P ¼ 0.02). Although the effect size associated with this CD4 þ cell increase was larger in women (À0.8%, P ¼ 0.01) than men (À0.3%, P ¼ 0.04), these differences were NS (P ¼ 0. Each 1 SD increased CTx over 24 weeks, or increased P1NP over 48 weeks, was associated with average spine BMD declines of 0.7% (P ¼ 0.02) and 1.1% (P < 0.0001; Supplementary Table, http://links.lww.com/QAD/ B354), respectively. The small number of women with turnover markers (n ¼ 19) precluded reliable comparisons by sex. If bone resorption was instead estimated by 48-week changes from baseline in CTx, the strength of association fell to a 0.5% average BMD decline (P ¼ 0.08). Plasma CTx and absolute CD4 þ cell counts were weakly correlated (r ¼ 0.16, P ¼ 0.01; r ¼ 0.12, P ¼ 0.06 and r ¼ 0.11, P ¼ 0.09 at weeks 0, 24 and 48, respectively).
Correlates of baseline hip bone mineral density Women had a 0.05 g/cm 2 (P ¼ 0.01) lower average baseline hip BMD than men in adjusted models. Baseline hip BMD was negatively associated with age (P < 0.0001), positively associated with baseline BMI (P < 0.0001) and black participants had larger baseline hip BMD than nonblacks (P ¼ 0.01). In contrast to the spine, serum phosphate was not associated with baseline hip BMD.
Baseline and time-varying correlates of 48-week hip bone mineral density change Participants randomized to TDF vs. non-TDF-containing regimens had a 1.5% (P < 0.0001) larger average hip BMD decline in adjusted models, and women had a 1.7% (P ¼ 0.001) larger decline than men. As with spine, hip BMD changes were positively associated with baseline hip BMD (P ¼ 0.001), negatively associated with baseline pVL (0.6% per each 1 log 10 greater HIV-RNA copies/ml; P U 0.003), and positively associated with pVL suppression to less than 50 vs. at least 50 copies/ml at week 48 (0.8% less BMD decline, P ¼ 0.01; Supplementary Table, http://links.lww.com/QAD/B354).
Changes in hip BMD were associated with baseline and DCD4 þ cells and turnover markers (Supplementary Table, http://links.lww.com/QAD/B354), but neither phosphaturia nor DGFR were associated with hip BMD changes. Each 100 fewer baseline CD4 þ cells/ml was associated with a 0.1% larger average BMD decline (P ¼ 0.02), whereas sex-modified associations with DCD4 þ , so that women had an average 0.6% more BMD decline than men for every 100 CD4 þ cells/ml increase (P ¼ 0.02 for the interaction by sex; n ¼ 48 women, 376 men; Fig. 2b) . In stratified analyses, this magnitude of CD4 þ increase was associated with an average BMD decline of 0.9% (P ¼ 0.003) in women, but DCD4 þ was not associated with BMD changes in men (P ¼ 0.59).
Each 1 SD increased CTx and P1NP over 48 weeks was associated with a 0.5% (P ¼ 0.02) and 0.7% (P ¼ 0.001) average hip BMD decline, respectively. In contrast to the spine, the strength of association with CTx fell to 0.3% (P ¼ 0.14) if bone resorption was instead estimated by 24-week changes from baseline in this marker.
Discussion
In this pooled analysis of two randomized trials comparing 48-week BMD changes with the initiation of TDF vs. non-TDF regimens in HIV-infected ARTnaïve persons, we observed significant differences in the correlates of bone loss that depended on bone site (spine Antiretroviral-therapy-associated bone decline Kalayjian et al. 2521 vs. hip), sex and TDF exposure. Participants randomized to TDF-containing regimens had accentuated spine BMD loss associated with phosphaturia, particularly among women. Women also had significantly more hip loss than men associated with CD4 þ restoration, regardless of TDF exposure. Despite overall spine and hip BMD declines of 2.8 and 2.9%, respectively, with initial ART, pVL suppression to less than 50 vs. at least 50 copies/ml was associated with 1.0 and 0.8% less BMD loss.
Bone turnover is a synchronized process of osteoclastderived resorption, osteoblast-derived collagen matrix deposition and mineralization. Plasma CTx, a marker of bone resorption, increases within 2 weeks after initiating ART, reaching peak levels by 24 weeks [20] . Plasma P1NP, a marker of new bone formation involving type I collagen matrix deposition, reaches peak levels approximately 1 year after ART initiation [21] . In the current study, the differential associations of spine vs. hip DBMD with DCTx when comparing 24-week and 48-week change from baseline of these turnover markers suggest earlier resorption of spine (predominately composed of trabecular bone) than hip (predominately cortical bone), a dynamic that is also evident with perimenopausal bone loss [22] .
The mineralization of collagen fibrils by osteoblasts incorporates carbonated hydroxyapatite, whose source of calcium and phosphate is derived from serum [23] . Serum phosphate is tightly regulated by parathyroid hormone and fibroblast growth factor 23 via intestinal phosphate absorption, and by phosphate reabsorption in the proximal renal tubules [24] . As in the current study, menopausal women retain phosphate, maintaining higher serum concentrations with lower urinary phosphate excretion than men or premenopausal women [25] . These observations point to possible contributions by menopausal bone loss to the differential associations by sex, between markers of phosphate homeostasis and changes in spine BMD. As bone mineralization is a late step in remodeling, the differential associations with phosphaturia between spine and hip similarly imply earlier remodeling of the spine.
Consistent with previous studies, participants randomized to TDF-containing regimens had significantly larger increases in bone turnover markers, which were associated with BMD declines [6, 13, 20, 26, 27] . TDF also may induce a proximal renal tubulopathy leading to urinary phosphate wasting, with or without GFR reductions, by engaging drug transporters in the renal tubular membrane [28] [29] [30] . The risk for tubulopathy may be accentuated by concomitant protease inhibitor use, including ritonavir, which also may directly engage these renal drug transporters, or enhance TDF exposure via drug-drug interactions [31, 32] . This tubulopathy has been postulated as a mechanism of BMD decline with TDF [26, 33] , but evidence for this effect is conflicting.
A previous analysis of A5224s participants did not detect an association between phosphaturia (as FEP) and hip or spine BMD changes [34] . In this subset, the association between FEP-AUC and spine BMD decline was NS among women (r ¼ 0.13, P ¼ 0.52, n ¼ 27), or in those randomized to TDF-containing regimens (r ¼ 0.14, P ¼ 0.18, n ¼ 90) probably because of the smaller sample size. In a second study of men with HIV receiving TDF, the urinary retinol-binding protein to creatinine ratio (a marker of renal tubule dysfunction), but not FEP, was negatively associated with spine BMD [35] . In a third longitudinal study of mostly men with HIV who received TDF, phosphaturia (as FEP) was negatively associated with femoral neck BMD decline, a site with approximately equal proportions of trabecular and cortical bone [36] . Tenofovir alafenamide (TAF) achieves higher intracellular accumulation, with lower plasma concentrations, and is associated with significantly less tubulopathy and BMD decline than TDF [37] . In adults with low BMD, switching from TDF to TAF was associated with increased hip BMD, which was predicted by higher FEP [38] . Although it is difficult to reconcile these disparate observations, the significant associations between phosphaturia as well as GFR changes, with early spine BMD loss in the current study supports an interpretation of TDF-mediated renal tubulopathy leading to impaired trabecular bone mineralization, particularly affecting women.
Among HIV-specific factors, CD4 þ cell increases, nadir CD4 þ cell counts and pre-ART pVL were previously associated with BMD loss after ART initiation [11, 20] . The importance of T-cell restoration in ART-associated bone loss is supported by an animal model simulating ART-associated immune restoration that adoptively transferred T cells from healthy mice into T-cell receptor knockout mice [39] . Consistent with the current study, CTx levels were previously correlated with CD4 þ cell counts in HIV patients who initiated ART [20] . We extend this observation by demonstrating more hip loss, for the same magnitude of CD4 þ restoration in women than men. Previous studies have demonstrated negative associations between BMD and pVL suppression on ART [40, 41] . Although we also observed net detrimental effects by initial ART on BMD, we detected salutary effects by pVL suppression.
The current study is limited by a relatively small number of women. Menstrual history and biological markers of menopause also were not captured in women, nor was the history of current or past tobacco or alcohol use among all participants. Bone turnover markers were measured in A5303 participants only, precluding reliable comparisons by sex with these markers. Nevertheless, the prospective study design with uniform measurements of BMD and other exploratory variables, in the context of randomized, initial ART regimens, are major strengths of this study.
Upon ART initiation, women who received TDF had enhanced spine BMD loss compared with men in association with phosphaturia. Women also had larger hip and spine BMD declines for the same magnitude of CD4 þ cell restoration as men, regardless of TDF exposure. Despite overall BMD declines with initial ART, viral suppression mitigated bone loss. The complex interactions that we observed involving bone site, sex and TDF exposure may be explained by simultaneous and overlapping effects of perimenopausal bone loss, TDFassociated bone toxicity, adverse bone effects by immune restoration and beneficial effects of viral suppression. Because of the importance of bone health among PLWH, a better understanding of these sex differences in ARTassociated BMD loss is warranted.
Interventions that have been shown to reduce early bone loss at the time of ART initiation include high-dose vitamin D and calcium supplementation and single-dose zoledronic acid [42, 43] . BMD also improves when switching from TDF to TAF [37] , or to other non-TDFcontaining regimens, but TDF remains a critical component of ART particularly in low-income countries where the majority of PLWH are women.
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